Expanding α-Synuclein Seed Amplification Assays Beyond Parkinson’s Disease: Advancing Biomarker Development in MSA & Rare Synucleinopathies
9:00 am - Wednesday 2nd December 2026
- Explore how α-synuclein seed amplification assays are enabling earlier, pathology-driven patient identification
- Examine the opportunities and challenges of applying emerging biomarker technologies in rare neurodegenerative diseases, where limited patient populations require innovative validation approaches
- Discuss how lessons learned from Parkinson’s disease biomarker development can accelerate clinical trial design, patient stratification, and therapeutic development in MSA and related disorders
